Literature DB >> 16179522

Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine.

Ashraf Virmani1, Franco Gaetani, Zbigniew Binienda.   

Abstract

A number of strategies using the nutritional approach are emerging for the protection of the brain from damage caused by metabolic toxins, age, or disease. Neural dysfunction and metabolic imbalances underlie many diseases, and the inclusion of metabolic modifiers may provide an alternative and early intervention approach that may prevent further damage. Various models have been developed to study the impact of metabolism on brain function. These have also proven useful in expanding our understanding of neurodegeneration processes. For example, the metabolic compromise induced by inhibitors such as 3-nitropropionic acid (3-NPA), rotenone, and 1-methyl-4-phenylpyridinium (MPP+) can cause neurodegeneration in animal models and these models are thought to simulate the processes that may lead to diseases such as Huntington's and Parkinson's diseases. These inhibitors of metabolism are thought to selectively kill neurons by inhibiting various mitochondrial enzymes. However, the eventual cell death is attributed to oxidative stress damage of selectively vulnerable cells, especially highly differentiated neurons. Various studies indicate that the neurotoxicity resulting from these types of metabolic compromise is related to mitochondrial dysfunction and may be ameliorated by metabolic modifiers such as L-carnitine (L-C), creatine, and coenzyme Q10, as well as by antioxidants such as lipoic acid, vitamin E, and resveratrol. Mitochondrial function and cellular metabolism are also affected by the dietary intake of essential polyunsaturated fatty acids (PUFAs), which may regulate membrane composition and influence cellular processes, especially the inflammatory pathways. Cellular metabolic function may also be ameliorated by caloric restriction diets. L-C is a naturally occurring quaternary ammonium compound that is a vital cofactor for the mitochondrial entry and oxidation of fatty acids. Any factors affecting L-C levels may also affect ATP levels. This endogenous compound, L-C, together with its acetyl ester, acetyl-L-carnitine (ALC), also participates in the control of the mitochondrial acyl-CoA/CoA ratio, peroxisomal oxidation of fatty acids, and production of ketone bodies. A deficiency of carnitine is known to have major deleterious effects on the CNS. We have examined L-C and its acetylated derivative, ALC, as potential neuroprotective compounds using various known metabolic inhibitors, as well as against drugs of abuse such as methamphetamine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179522     DOI: 10.1196/annals.1344.016

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  Infant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity.

Authors:  K B Bjugstad; L S Crnic; S I Goodman; C R Freed
Journal:  J Inherit Metab Dis       Date:  2006-08-30       Impact factor: 4.982

Review 2.  The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors.

Authors:  Jing Du; Ming Zhu; Hongkun Bao; Bai Li; Yilong Dong; Chunjie Xiao; Grace Y Zhang; Ioline Henter; Matthew Rudorfer; Benedetto Vitiello
Journal:  Crit Rev Food Sci Nutr       Date:  2016-11-17       Impact factor: 11.176

3.  Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.

Authors:  Dustin P Brown; Dennis T Rogers; Francois Pomerleau; Kirin B Siripurapu; Manish Kulshrestha; Greg A Gerhardt; John M Littleton
Journal:  Fitoterapia       Date:  2016-04-20       Impact factor: 2.882

4.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.

Authors:  W H Xiao; H Zheng; G J Bennett
Journal:  Neuroscience       Date:  2011-12-20       Impact factor: 3.590

5.  cPLA2 is protective against COX inhibitor-induced intestinal damage.

Authors:  David C Montrose; Krishna Kadaveru; Jillian N M Ilsley; Sierra H Root; Thiruchanduri V Rajan; Manish Ramesh; Frank C Nichols; Bruce T Liang; Dmitry Sonin; Arthur R Hand; Simona Zarini; Robert C Murphy; Glenn S Belinsky; Masako Nakanishi; Daniel W Rosenberg
Journal:  Toxicol Sci       Date:  2010-06-18       Impact factor: 4.849

6.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.

Authors:  Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

7.  L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.

Authors:  Hussam A S Murad
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

8.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.

Authors:  Hai Wei Jin; Sarah J L Flatters; Wen Hua Xiao; Howard L Mulhern; Gary J Bennett
Journal:  Exp Neurol       Date:  2007-11-17       Impact factor: 5.330

Review 9.  Food, nutrigenomics, and neurodegeneration--neuroprotection by what you eat!

Authors:  Ashraf Virmani; Luigi Pinto; Zbigniew Binienda; Syed Ali
Journal:  Mol Neurobiol       Date:  2013-06-28       Impact factor: 5.590

Review 10.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.